First Trust Advisors LP Raises Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

First Trust Advisors LP lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 15.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 106,686 shares of the medical equipment provider’s stock after buying an additional 13,993 shares during the period. First Trust Advisors LP’s holdings in Lantheus were worth $7,503,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Fairfield Bush & CO. acquired a new stake in shares of Lantheus during the 1st quarter valued at approximately $177,000. Raymond James & Associates acquired a new position in Lantheus in the 1st quarter worth $856,000. Bank of New York Mellon Corp lifted its holdings in Lantheus by 2.7% in the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock worth $34,791,000 after buying an additional 16,422 shares in the last quarter. American Century Companies Inc. increased its position in shares of Lantheus by 14.4% in the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock worth $1,064,000 after purchasing an additional 2,427 shares during the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of Lantheus in the 1st quarter worth about $354,000. Institutional investors and hedge funds own 97.62% of the company’s stock.

Lantheus Stock Performance

LNTH opened at $70.75 on Tuesday. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.59 and a current ratio of 2.74. The business’s 50-day simple moving average is $60.03 and its 200 day simple moving average is $63.82. The firm has a market capitalization of $4.78 billion, a PE ratio of 208.09 and a beta of 0.64. Lantheus Holdings, Inc. has a 52-week low of $47.46 and a 52-week high of $87.47.

Lantheus (NASDAQ:LNTH – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.41. The business had revenue of $263.17 million for the quarter, compared to the consensus estimate of $244.61 million. Lantheus had a return on equity of 51.60% and a net margin of 3.00%. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of research analyst reports. JMP Securities initiated coverage on shares of Lantheus in a research note on Wednesday, March 8th. They issued an “outperform” rating and a $120.00 price target for the company. SVB Leerink began coverage on shares of Lantheus in a research note on Wednesday, November 30th. They set an “outperform” rating on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, February 27th. Finally, Mizuho raised their price target on shares of Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, February 24th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

Insider Buying and Selling

In other Lantheus news, CAO Andrea Sabens sold 7,705 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $72.56, for a total value of $559,074.80. Following the sale, the chief accounting officer now owns 63,626 shares of the company’s stock, valued at approximately $4,616,702.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Lantheus news, CAO Andrea Sabens sold 7,705 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $72.56, for a total value of $559,074.80. Following the sale, the chief accounting officer now owns 63,626 shares of the company’s stock, valued at approximately $4,616,702.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Mary Anne Heino sold 10,064 shares of the stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $74.70, for a total value of $751,780.80. Following the completion of the transaction, the chief executive officer now owns 719,397 shares of the company’s stock, valued at $53,738,955.90. The disclosure for this sale can be found here. Insiders have sold 152,801 shares of company stock valued at $11,138,348 over the last 90 days. 1.60% of the stock is owned by corporate insiders.

Lantheus Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.